Microbot Medical achieved a dual clinical breakthrough as Emory Healthcare completed the world’s first robotic prostatic artery embolization for benign prostatic hyperplasia and the first robotic Y-90 radioembolization mapping for liver cancer. Both procedures were performed using Microbot’s proprietary endovascular robot system, demonstrating its precision and versatility in minimally invasive interventions.

In the prostatic artery embolization, Microbot’s robot guided microcatheters to block blood flow to enlarged prostate tissue, relieving urinary symptoms without traditional surgery. This marks a significant advancement in urology, offering patients a lower-risk alternative to transurethral resection with faster recovery times.

For Y-90 mapping, the robotic system delivered precise radiolabeled microspheres to liver tumors, enabling accurate dosimetry planning prior to full radioembolization therapy. This capability could improve treatment outcomes in interventional oncology by optimizing dose distribution and reducing off-target effects.

Successful completion of these first-in-human procedures provides critical clinical validation for Microbot’s platform, positioning the company to pursue expanded trials and commercial partnerships. Widespread adoption in leading health systems could drive revenue growth and strengthen Microbot’s leadership in the surgical robotics market.